Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202 was written by Ruppert, Amy S.;Booth, Allison M.;Ding, Wei;Bartlett, Nancy L.;Brander, Danielle M.;Coutre, Steven;Brown, Jennifer R.;Nattam, Sreenivasa;Larson, Richard A.;Erba, Harry;Litzow, Mark;Owen, Carolyn;Kuzma, Charles S.;Abramson, Jeremy S.;Little, Richard F.;Smith, Scott E.;Stone, Richard M.;Byrd, John C.;Mandrekar, Sumithra J.;Woyach, Jennifer A.. And the article was included in Leukemia in 2021.Recommanded Product: 16506-27-7 The following contents are mentioned in the article:
Ibrutinib has superior progression-free survival compared with bendamustine plus rituximab (BR) in older CLL patients, however, differences in treatment duration, six monthly BR cycles vs. continuous ibrutinib, complicate adverse event (AE) comparisons. We introduce the AE burden score (AEsc) to compare AEs, calculated for each patient by summing over products of reporting period length and grade for each all-cause grade 1-4 AE and dividing by the length of time over which AEs are assessed. A total of 176 patients received BR and 361 ibrutinib alone or with six cycles of rituximab. At 38 mo median follow-up, 64% remained on ibrutinib. Median AEsc was higher with BR vs. ibrutinib in the first six cycles (7.2 vs. 4.9, p < 0.0001). Within ibrutinib arms, median AEsc decreased significantly to 3.7 after six cycles (p < 0.0001). 10% and 14% of BR and ibrutinib patients discontinued treatment for AEs. In ibrutinib arms, cumulative incidence of grade 3 or higher atrial fibrillation, hypertension, and infection (AEs of clin. interest) at 12 mo was 4.5%, 17.5%, and 12.8%, resp., and increased more slowly thereafter to 7.7%, 25.4%, and 20.5% at 36 mo. Anal. tools including the AEsc and cumulative incidence of AEs can help to better characterize AE burden over time. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Recommanded Product: 16506-27-7).
4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole has been usedin the lysis, wash and elution buffer for the purification of histidine tagged Sonic Hedgehog(shh-N) protein, in elution buffer in stepwise gradient for the purification of histidine tagged aldo keto reductases using nickel affinity chromatography, as a component of homogenization buffer for the purification of phagosomal compartments from dendritic cells.Recommanded Product: 16506-27-7
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem